PURPOSE We evaluated the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation on the re-intervention rate in women with ductal carcinoma in situ (DCIS) undergoing breastconserving surgery.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is managed through a combination of surgery and radiation therapy.
1,2 For smaller DCIS, breast-conserving surgery (BCS) is increasingly performed over mastectomy, on the basis of studies demonstrating equivalent survival rates in patients with invasive breast cancer. 3 Complete tumor excision is key to successful BCS, but cannot always be achieved in the first surgery because of difficulty in accurately assessing tumor size and extent. Positive or close margins at initial resection have been reported in 17% to 58% of DCIS lesions, 4 requiring patients to undergo re-excision. Re-excision is associated with increased potential complications and patient stress and costs; it also lead to additional mastectomies. 5 The role of breast magnetic resonance imaging (MRI) in the preoperative assessment of DCIS remains controversial and is not yet established. Several studies have shown the superior sensitivity of MRI in detecting DCIS compared with mammography. [6] [7] [8] [9] [10] [11] In addition, there is growing evidence that MRI may provide more accurate information on the extent of DCIS lesions, although it has been reported to both underestimate and overestimate tumor size compared with mammography. 8, [12] [13] [14] [15] [16] Nevertheless, retrospective studies found that preoperative MRI assessment of DCIS was not associated with reduced re-excision rates, bringing into question the impact of MRI on patient outcome. [17] [18] [19] [20] Furthermore, another retrospective analysis of a cohort of 2,321 women with DCIS who underwent BCS found no association between preoperative MRI and lower locoregional recurrence rates. 21 Recently, a meta-analysis on MRI and DCIS staging reported no input of MRI to improve local surgery. 22 However, there have been no clinical trials conducted specifically in patients with DCIS undergoing BCS to fully evaluate the role of preoperative MRI.
We undertook a multicenter, prospective randomized superiority trial to determine whether the addition of MRI to standard radiologic evaluation could improve assessment of tumor extension and reduce the re-intervention rate in women with DCIS scheduled for BCS. We report the primary end point of the trial (the re-intervention rate for positive or close margins at 6 months) and some secondary end points.
PATIENTS AND METHODS

Patients
This trial was designed to evaluate the efficacy of adding MRI to standard radiologic evaluation (mammography and ultrasound) in the reduction of the re-intervention rate. Ten French hospitals participated in the trial. Women between 18 and 80 years of age with a biopsy-proven limited breast DCIS, corresponding to a unifocal microcalcification cluster or a mass less than 30 mm, and scheduled for BCS, were eligible for the study. Exclusion criteria were patients with invasive carcinoma; with microcalcification foci inaccessible to biopsy; with bilateral lesions; with known contraindications to MRI; who refused surgery, including mastectomy if necessary; with a history of ipsilateral breast cancer; who were at high risk for breast cancer (BRCA1 or 2 mutations); and who were pregnant or breastfeeding. All patients provided written informed consent. This trial was approved by local research ethics committees and was registered at ClinicalTrials.gov (NCT01112254; IRCIS trial).
Randomization
Patients were randomly assigned to one of two arms, MRI or no MRI (standard radiologic evaluation without MRI), with a 1:1 allocation ratio. The allocation of the patients between the two arms was performed with block randomization stratified by center, the size of the blocks being randomly chosen between two, four, six, and eight for each new center block. Randomization was performed with TENAlea software, version 2.2 (TransEuropean Network for Clinical Trial Services, Amsterdam, the Netherlands).
Procedures
Before randomization, all patients underwent clinical examination, mammography, and percutaneous biopsy, per standard protocol. In the experimental arm, MRI was performed mainly on 1.5T systems and on 3T systems in two centers, as follows: T1-weighted spin-echo sequences and T2-weighted fast spin-echo sequences with or without fat suppression before injection of contrast agent, and 3D gradient-echo sequences with or without fat suppression after contrast agent injection, according to each hospital's equipment and MRI protocol, while respecting slice thickness less than 3 mm and high resolution (. 256). In case of enhancement suggestive of a mass or multiple and large lesions (. 3 cm from the initial lesion) on MRI, second-look ultrasound or additional mammography with magnification views were performed. If indicated, biopsy was then performed with mammography, ultrasound, MRI, or computed tomography guidance. The type of surgery (lumpectomy, extensive surgery, or mastectomy) was determined according to MRI and biopsy results. In the control arm, patients underwent surgery without additional diagnostic examinations. In both arms, re-excision for positive or close margins had to be performed in the 2 months after initial surgery.
Statistical Analysis
The objective of the study was to obtain a 50% relative reduction in the re-intervention rate, which was estimated at 25% in the control arm on the basis of published literature. 4, 23 To detect a 50% relative reduction (25% to 12.5%) in the MRI arm, we needed to include 360 patients (bilateral test: alpha, 5%; power, 80%), allowing for a 7% rate of dropout or noncompliance.
The primary end point was the re-intervention rate for positive or close margins (, 2 mm) in the 6 months after randomization. The re-intervention rate was compared between the two arms, with a logistic analysis stratified by center. Analysis was performed with the intent-to-treat principle, after excluding patients with major violation of the eligibility criteria. Sensitivity analyses were conducted, including for all randomly assigned patients and the perprotocol population.
The secondary end points included the mastectomy rate (at initial surgery and subsequently), the most common MRI imaging criteria for DCIS, including morphologic and kinetic criteria, which were described with usual descriptors, and finally, an economic evaluation (which will be published separately). The mastectomy rate at initial surgery was analyzed using the same methods as for the primary end point. All analyses were performed with SAS 9.3 or 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient and Lesion Characteristics
A total of 360 patients were included from March 2010 to June 2014, with 181 patients in the MRI arm and 179 in the control arm. Figure 1 shows the study flowchart. Eight patients had a major violation of the eligibility criteria (three and five in the MRI and control arms, respectively) and were removed from subsequent analyses (Fig 1) . The baseline characteristics of the remaining 352 patients, (178 patients in the MRI arm and 174 in the control arm) are listed in Table 1 . Most patients were 50 years of age or older and postmenopausal. The majority of patients had Breast Imaging-Reporting and Data System 4 lesions (82% in the MRI arm, 83% in the control arm) and presented with microcalcification clusters (98% in the MRI arm, 99% in the control arm) visible on mammography. The median size was 10 mm on mammography (1 to 30 mm; 47% were , 10 mm, n = 143; 33% were 11 to 20 mm, n = 107; 20% were . 20 mm, n = 67) and on ultrasound (0 to 30 mm).
In 10 patients, 11 borderline lesions were detected on initial biopsy before MRI (seven patients in the MRI arm and three in the control arm), with one patient in the MRI arm presenting with two lesions associated with DCIS. In nine patients, the borderline lesion was found in the same breast as the DCIS lesion. Eight lesions were histologically confirmed to be atypical ductal hyperplasia (ADH; n = 2), atypical lobular hyperplasia (ALH; n = 1), ADH plus ALH (n = 1), ductal hyperplasia without atypia (n = 1), flat epithelial atypia (n = 1), lobular carcinoma in situ (n = 1), and atypical ductal atypia (n = 1), the last two lesions being found in the same patient.
MRI Procedures
In the MRI arm, nine patients of 178 did not undergo MRI, whereas in the control arm, three of 174 underwent MRI (Fig 1) . Of 169 patients who underwent MRI in the MRI arm, 41 of 167 patients with available data (25%) had one or more additional lesions detected by MRI, presenting with a total of 54 additional lesions. Thirty patients had one additional lesion detected, nine had two additional lesions, and two patients had three additional lesions. 
Journal of Clinical Oncology
Among the 41 patients with MRI-detected lesions, 25 (61%) had all the additional lesions in the same breast as the initial DCIS lesion, whereas 16 (39%) had at least one additional lesion in the contralateral breast. On the basis of MRI results, 33 patients underwent one or more additional biopsies for the initial 9 or additional lesions, 24 among whom 12 had an MRI-guided biopsy. Twenty-six patients had one additional biopsy, and seven patients had two additional biopsies. For 31 of the additional lesions detected by MRI with available biopsy data, 18 (58%) were benign, 11 (35%) were malignant or high risk, one (3%) was questionable, and one (3%) was nonsignificant. The 11 malignant or high-risk lesions were histologically confirmed as follows: invasive ductal carcinoma (n = 3), DCIS (n = 5), lobular carcinoma in situ (n = 1), ALH (n = 1), and ADH plus papillary cancer (n = 1). For the nine more extensive index lesions, one was nonsignificant, one was benign, and seven were malignant (four DCIS, three invasive ductal carcinoma; Fig 2) . In total, for the 40 biopsied additional lesions or more extensive index lesions, the false-positive rate was 52% (21 of 40, of which 19 were benign and two were normal tissue). The exploratory results (Appendix Fig A1, online  only) give effects of MRI (stratified odds ratios [ORs] with their 95% CIs) in different subpopulations. The P values for different effects (interaction) for breast density (P = .60), age (P = .93; trend P = .99), type of MRI (P = .84), lesion size (P = .34; trend P = .87), and center (P = .94) do not suggest subpopulations of interest where MRI could be further evaluated in subsequent trials.
BCS With and Without Preoperative MRI
The median largest size of surgical specimens was not statistically different between the two arms: 60 (range, 15 to 440 mm) in the MRI arm and 59 (21 to 250 mm) in the control arm (P = .11). If restricted to lumpectomy specimens only, the median largest size was 60 mm (range, 15 to 440 mm) in the MRI arm and 57 mm (21 to 175 mm) in the control arm (P = .39).
In the MRI arm, 69% of surgical specimens (120 of 174) were larger than 50 mm, and only 61% were in the standard arm (103 of 170). The additional excision rate in the same surgery was also not statistically different between the two arms: 54% (n = 95) in the MRI arm and 51% (n = 88) in the control arm (P = .59). An invasive component, alone or associated with DCIS, was found in 17 (10%) lesions in the MRI arm and in 26 (15%) in the control arm (P = .13 and nonsignificant, respectively). Neither the size of the DCIS component, 20 mm (1 to 120 mm) in the MRI arm and 18 mm (1 to 97 mm) in the control arm (P = .99), nor the size of the invasive component, 4 mm (2 to 24 mm) in the MRI arm and 7 mm (2 to 50 mm) in the control arm (P = .41) was different between the two arms. Furthermore, neither DCIS grade (P = .79) nor grade of the invasive component (P = .77) was statistically different between the two arms. Five bilateral surgeries were performed in the MRI arm, and one malignant lesion was removed (DCIS). The contralateral cancer rate detected on MRI was therefore 0.6% (1 of 165).
At the first surgery, patients with lesions not removed at biopsy and surgical margins larger than 2 mm were 78 of 139 (56%) in the MRI arm and 70 of 147 (48%) in the control arm (P = .15). We had missing margins for 22 patients.
In the MRI arm, six malignant lesions (three with positive or close margins) were finally not seen on MRI, after initial biopsy. In the control arm, eight malignant lesions (six with positive or close margins) were also not detected on mammogram with or without ultrasound. There was no statistical difference between arms on additional lesions detected with MRI (P = .60).
Re-Intervention Rate
Information on re-intervention in the 6 months after randomization was not available for seven patients because of death (n = 1), consent withdrawal (n = 2), or loss to follow-up (n = 4). The intent-to-treat analysis was therefore conducted in 173 patients in the MRI arm and 172 patients in the control arm. In total, 82 of 345 patients were reoperated for positive or close margins at 6 months after randomization. In the MRI arm, 35 patients (20%) were reoperated, compared with 47 patients (27%) in the control arm. The absolute difference of 7% (95% CI, 22% to 16%), which corresponds to a relative reduction of 26% (7 of 27), was not statistically significant (stratified OR, 0.68; 95% CI, 0.41 to 1.1; P = .13). When all 360 patients were considered, without excluding any patients, the resulting stratified OR was 0.66 (95% CI, 0.40 to 1.1) with a P value of .11. However, when considering the per-protocol population with an assessable end point (165 patients in the MRI arm and 169 in the control arm), the absolute difference was 9%, which corresponded to a 36% relative difference (stratified OR, 0.59; 95% CI, 0.35 to 1.0) with a P value of .05.
Rate of Mastectomy
For the initial surgery (data available for 349 patients), mastectomy was performed in 16 of 176 patients (9%) in the MRI arm and seven of 173 patients (4%) in the control arm, corresponding to an absolute difference of 5% (95% CI, 0% to 10%; stratified P = .06) in excess in the MRI arm. For seven patients in the control arm, mastectomy was chosen because of the patient's preference (n = 3), detection of an additional lesion on preoperative mammography (n = 1), a multicentric lesion (n = 1), small breasts that had already been operated (n = 1), and an unspecified reason (n = 1). In the MRI arm, mastectomy was performed in case of larger or residual lesions seen on MRI and confirmed histologically. We also evaluated the total rate of mastectomy after the initial surgery: 15 mastectomies were performed during a second surgery in the MRI arm (9%), as well as 23 in the control arm (13%). Thus, the total mastectomy rate was 18% (31 of 176) in the MRI arm and 17% (30 of 173) in the control arm (stratified P = .93). Of the 41 patients who had additional lesions detected on MRI, eight patients (20%) had mastectomy (initial surgery).
Radiation Therapy After Surgery
Among the patients with lumpectomy and DCIS as the final histology of the main lesion and no other malignant lesions detected, the rate of radiation therapy was 117 of 140 (83%) in the MRI arm and 119 of 143 (83%) in the control arm.
MRI Morphologic and Enhancement Parameters
For the 169 patients in the MRI arm who underwent MRI after biopsy, the inclusion lesion was seen in 100 patients (60%). The great majority of DCIS lesions were found to be nonmasslike enhancement, as opposed to mass enhancement (82% and 20% respectively, given that for two lesions, both enhancement types were found; Table 2 ). The most common MRI findings were focal (n = 31; 39%) and linear enhancement (n = 28; 35%), with nodular internal (n = 27; 35%) and heterogeneous enhancement (n = 27; 35%). However, we did not find any specific kinetic parameters that were predominant in DCIS: type 1 progressive curve (n = 19; 37%), type 2 plateau curve (n = 14; 27%), and type 3 washout curve (n = 18; 35%). 
DISCUSSION
To our knowledge, this was the first multicentric, prospective randomized controlled trial evaluating the role of preoperative MRI assessment specifically in patients with limited DCIS. The main objective of the study, which was a 50% relative reduction in the re-intervention rate in the MRI arm, was not achieved. Although this objective may have been ambitious, this was the level of reduction judged clinically relevant. We found an absolute difference of 7%, corresponding to a nonsignificant 26% relative reduction in the re-intervention rate (P = .13). However, in the per-protocol analysis, we found a statistically significant absolute difference of 9% (P = .05). Because intention-to-treat analysis is the adequate method to analyze a randomized trial, we consider that the intention-to-treat results are to be preferred to the per-protocol analysis, although the latter always brings interesting complementary information. In our study, both carried a similar message.
Two large randomized controlled trials have evaluated the use of preoperative MRI in patients with breast cancer, one of which did not find any difference in reoperation rates, and the other found a paradoxical association of MRI with an increased reexcision rate. 25, 26 Furthermore, a recent meta-analysis on preoperative MRI in patients with invasive breast cancer found no association between preoperative MRI and improved surgical outcomes. 27 In this prospective study, which to our knowledge is the first to focus on patients with DCIS, the nonsignificant relative reduction of 26% in the re-intervention rate does not favor the use of preoperative MRI in DCIS staging in its current state. The role of preoperative MRI may need to be reevaluated, however, with future improvement in MRI techniques 24 and better understanding of DCIS-specific MRI parameters.
Our study was focused on surgical strategy in patients with small DCIS. In this purpose, we chose the re-intervention rate for positive margins as the primary end point rather than positive margins alone. In this trial, we were interested in establishing the role of MRI real-life DCIS surgery and staging. As expected for small DCIS, the rate of invasive component or high-grade lesions was low. Thus, results may be not as positive for MRI in comparison with other retrospective studies that aimed at evaluating the input of breast MRI in prognosis or the invasive component associated with DCIS. 11, 28 These studies underlined the input of MRI in high-grade DCIS or extensive DCIS in comparison with conventional imaging. 11, 28 Although MRI may contribute to better detecting lesions and assessing tumor size, it has also been argued that it could lead to overtreatment of low-risk DCIS lesions, increased patient anxiety and costs, unnecessary wider excisions, and more mastectomies. 29 In this regard, the total mastectomy rate that remained below 20% in the MRI arm and was not different from that in the control arm in this study is reassuring, suggesting that the addition of MRI did not lead to overuse of mastectomy. Of note, in our study, MRI examination did not lead to as many MRI-guided biopsies (12 of 42 patients undergoing additional biopsies, among 169 patients in the MRI arm), because most lesions were visible on second-look ultrasound or additional mammography.
This study has limitations. The majority (82%) of DCIS showed nonmass-like enhancement, which made the MRI interpretation challenging. In our study, we realized that the main difficulty for the surgeons was to practically use MRI information to achieve BCS according to MRI results. Indeed, some MRI lesions were so subtle and not specific that the information was not considered during surgery. In addition, it is possible that biopsy changes made the interpretation more difficult. Nevertheless, these results may probably more mimic real-life surgical practices, because it was prospective and conducted in specialized breast centers.
In summary, our study results did not show sufficient surgical improvement with the use of preoperative MRI to be clinically relevant in DCIS staging. However, this might be reconsidered with the improvement of new MRI sequences in future development. 
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